Liraglutide (Saxenda) and semaglutide (Wegovy) are GLP‐1R agonists approved by the United States Food and Drug Administration for obesity treatment in 2014 and 2021, promoting the belief that breakthrough, drug‐based management of obesity may be possible.264, 278, 279. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.